Neurocrine Biosciences NBIX Crushes Q2 2026 EPS by 44%
As seen on the 24/7 Wall St. homepage on July 30, 2026.
Neurocrine demolished EPS expectations by 44% and hiked full-year INGREZZA guidance after the $2.9 billion Soleno acquisition added $54 million in revenue and positioned the biotech's pipeline for major 2027 clinical readouts in depression and schizophrenia.
Continue ReadingShow less
Neurocrine Biosciences reported Q2 2026 earnings per share of $2.85, well ahead of the $1.98 consensus estimate and the company's strongest beat in recent quarters. Revenue came in at $959 million, topping expectations of roughly $890 million by nearly 8%. The results also prompted management to raise its full-year guidance for INGREZZA, the company's flagship tardive dyskinesia treatment.
A significant driver of the outperformance was the $2.9 billion acquisition of Soleno, which contributed $54 million in revenue during the quarter. The deal not only added immediate top-line impact but also broadened Neurocrine's pipeline heading into a pivotal period for the company.
Sponsored
_________________________________
What's Your Number...?
Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
Investors will now be watching 2027 closely, when Neurocrine expects major clinical readouts in depression and schizophrenia. Those results will be a key test of whether the Soleno acquisition and the expanded pipeline can sustain the growth momentum that sent Q2 results well past what Wall Street had modeled.
Mentioned: NBIX